The purpose of this requirement is to 1) provide medical countermeasures (mcms), such as vaccines and adjuvants, for pandemic preparedness and response or as required in response to a HHS designated…
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75A50122D00002
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Task orders
- 20 $109,499,184 obligated
Award facts
- Opportunity
-
- Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response Solicitation · 75A50121R00013 · Posted Jun 29, 2021
- Combined order value
-
- $109,499,184 Current, with exercised options
- $188,044,867 Potential, with all options
- Last date to order 93% complete
- IDV ceiling 2% used
- $4,687,707,199.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Office of the Assistant Secretary for Preparedness and Response awarded a single-award Indefinite Delivery Contract (IDC) valued at $4.69 billion to Glaxosmithkline, LLC effective February 22, 2022, through February 21, 2027. This civilian agency contract facilitates the procurement of medical countermeasures, including vaccines, adjuvants, and related pharmaceutical products, to support pandemic preparedness and response activities. The contract encompasses a comprehensive range of services including Current Good Manufacturing Practice (CGMP) manufacturing of influenza vaccine master and working seed lots, investigational and commercial bulk vaccine lots, formulation and fill-finish activities for vaccine delivery systems, physical and chemical compatibility studies, stability testing and long-term storage of bulk lots and final containers, and clinical trial support. Primary performance locations are Research Triangle Park and Durham, North Carolina, with Glaxosmithkline maintaining manufacturing and storage capabilities at both sites. The contract utilizes firm-fixed-price delivery orders with no set-aside designations, and performance is led by the prime contractor, a foreign-owned, for-profit pharmaceutical company with established expertise in vaccine development and production.
Through eighteen task orders issued between February 2022 and June 2025, the contract has supported critical national health security initiatives with delivery values ranging from $62,952 to $94.59 million per order. Notable task orders include H5 pandemic readiness procurement valued at $94.59 million, COVID-19 vaccine adjuvant (AS03) fill-finish and storage services totaling approximately $41 million combined, procurement of egg-based influenza master and working seed lots derived from H5N1 candidate vaccine virus strains valued at $1.65 million, and clinical trial support for the Influenza A/Astrakhan/3212/2020 (H5N8) vaccine candidate at $22.88 million. Additional orders address storage and stability services for antigens and adjuvants, procurement of CGMP adjuvants for clinical and commercial scale production, and Department of Defense support for AS03 adjuvant fill-finish activities. These task orders demonstrate the contract's strategic focus on maintaining domestic vaccine manufacturing capacity, developing medical countermeasures against emerging influenza threats, and ensuring long-term stability and availability of critical pandemic response assets through 2027.
Description
The purpose of this requirement is to 1) provide medical countermeasures (mcms), such as vaccines and adjuvants, for pandemic preparedness and response or as required in response to a HHS designated public health emergency. 2) produce vaccines AG
Task orders
Show all 20
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Show all 14
Quick answers
Who was awarded contract 75A50122D00002?
75A50122D00002 was awarded to Glaxosmithkline, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 22, 2022.
How much is contract 75A50122D00002 worth?
Orders under 75A50122D00002 have obligated $109,499,184. Their combined potential value, with all options, is $188,044,867. 75A50122D00002's own ceiling is $4,687,707,199.
How many orders have been placed under contract 75A50122D00002?
20 orders have been placed under 75A50122D00002, the latest on September 1, 2026.
Who can order from contract 75A50122D00002?
75A50122D00002 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75A50122D00002 competed?
The extent of competition for 75A50122D00002 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV